 (SURGERY 1995;117:705-11.) 
mucosal endocrine cells, which suggests a hormonal role. 8 Harper et al. 9 ,10 demonstrated that extracts from colonic and ileal mucosa of cats and pigs markedly inhibited both pancreatic protein secretion and gall bladder contraction. Intraluminal perfusion of the colon with nutrients induces endocrine effects* 6 Per fusion of the colon with oleic acid inhibits the release of cholecystokinin and pancreatic enzyme secretion in dogs. 15 Moreover, it has been shown that subtotal colectomy results in an increased postprandial chole cystokinin release in rats and dogs. 17, 18 These findings suggest that the colon contains a factor that suppresses the release of cholecystokinin. Little is known, however, about the effects of proctocolectomy on gastrointestinal physiology and circulating gut hormone responses in human beings.
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The aim of this study was to examine the effect of proctocolectomy with IPAA on the release of cholecystokinin and gallbladder motility in human beings. Therefore we have studied fasting and postprandial plasma cholecystokinin levels and gallbladder volumes (GBVs) in these patients. The results were compared with those obtained in healthy volunteers. To study the release of cholecystokinin independently of a meal, we further have studied cholecystokinin secretion during intravenous administration of bombesin, a neuropeptide that potently stimulates the release of cholecystoki- * 19-21 mn.
METHODS
Subjects. Twelve healthy subjects (seven male and five female) and 10 patients who had undergone proc tocolectomy with IPAA (three male and seven female; three cases of familial polyposis coli and seven cases of ulcerative colitis) were studied. In all patients a J pouch had been constructed 6 months to 7 years (median, 4 years) before this study was performed. The diverting loop ileostomy had been closed in all. None of the pa tients with IPAA had experienced pouchitis. M ean age, weight, length, and body mass index (BMI) were sim ilar in both groups (Table) . None of the healthy subjects had a history of previous abdominal operation or gas trointestinal disease, and none of the patients with IPAA had undergone cholecystectomy. Fasting plasma chole cystokinin levels were determined in an additional five patients with IPAA and three healthy volunteers (both groups, total 15 subjects). To assess whether postpran dial plasma cholecystokinin levels change with time of follow-up, the correlation between the integrated post prandial plasma cholecystokinin levels and the length of time after operation was calculated. Informed consent was obtained from each subject, and the protocol was approved by the Ethics Committee of the Nijmegen University Hospital.
Experimental protocol* All subjects reported at 8:30 AM at the gastrointestinal research laboratory after an overnight fast. The subjects ingested a standardized breakfast (at t = 0 minutes) composed of one slice of bread, 5 gm butter, 20 gm cheese, one boiled egg, 150 ml yogurt, and one cup of tea with 5 gm sugar (21 gm protein, 2 1 .5 gm fat, 34 gm carbohydrate). Venous blood samples for analysis of plasma cholecystokinin levels were drawn before (at t = [ < ] 0m;-5 and 0 minutes) and at 15-minute intervals from 0 to 120 minutes and at 30-minute intervals from 120 to 180 minutes after the meal through an indwelling catheter placed in an antecubital vein. Blood was collected into glass tubes containing ethylenediamine tetraacetic acid. After cen trifugation the separated plasma was frozen at -20° C until analysis. GBVs were measured at the same time points.
In a second experiment the response of plasma chole cystokinin to intravenous administration of bombesin (5 ng/kg/m in) was measured in six patients with IPAA (two male and four female; mean age, 34 years; range, 23 to 41 years) and five healthy volunteers (three male and two female; mean age, 47 years; range, 43 to 53 years) after an overnight fast, Three of the six patients with IPAA had also participated in the first experiment. None of the patients with IPAA had experienced epi sodes with pouchitis. None of the healthy volunteers in the bombesin experiment had participated in the first experiment. Bombesin was administered through an indwelling catheter in an antecubital vein. Blood sam ples for determination of plasma cholecystokinin levels were drawn from a catheter in an antecubital vein in the opposite arm before and at 5-minute intervals for 20 minutes during bombesin infusion.
G allbladder emptying. GBV was measured by means of real-time ultrasonography with the sum of cylinders method by using a computerized method. 22 In this method the longitudinal scan of the gallbladder is divided into a series of cylinders of equal height, with diameters perpendicular to the longitudinal axis of the gallbladder image. The uncorrected volume is the sum of volumes of these separate cylinders. To correct for the displacement of the longitudinal image of the gallblad der from the central axis, a correction factor is calculated from the longitudinal and transverse scans of the gall bladder. GBV is calculated by multiplication of the un corrected volume with the square of the correction fac tor. Two longitudinal and two transverse images of the gallbladder were obtained at each time point. The mean of two measurements was used for further analysis. The variation of GBV measurements by using this method ranges from 6.2% to 10.0%. Gallbladder emptying and percentage gallbladder emptying were calculated by using the following formulas:
where GBVo is mean fasting GBV (average of GBV at t = ~5 and 0 minutes) and GBVm¡n is smallest post prandial GBV.
Plasm a cholecystokinin levels. Cholecystokinin was measured in plasma by a sensitive and specific radioim munoassay.231 24 The antibody used (T204) was raised in rabbit after the fourth immunization with albumincoupled crude porcine cholecystokinin and used in a fi nal dilution of 1:80,000. The antibody binds to all carboxy-terminal cholecystokinin peptides containing the sulfated tyrosyl region. The antibody shows less than 2% cross-reactivity with sulfated gastrins and does not bind to unsulfated forms of gastrin or structurally unrelated peptides, like insulin, secretin, pancreatic polypeptide, bombesin, and neurotensin. Synthetic human cholecystokinin33 coupled to 125I-hydroxyphenylpropionic acid succinimide ester (Bolton-Hunter reagent) was used as label and as standard preparation. The detection limit of this assay is 0.5 pmol/L. The intraassay variation ranges from 4.6% to 11.5% and the interassay variation from 11.3% to 26.1 7ö.
Statistical analysis. Results were expressed as mean ± SEM. Fasting plasma cholecystokinin levels and fasting GBVs were calculated as the mean of two basal measurements (-5 and 0 minutes). Integrated plasma cholecystokinin secretion in response to the meal or to bombesin infusion was determined by calculating the area under the plasma concentration versus time curve by using the trapezoidal rule. Statistical analysis was performed with Student's t test for unpaired results or the rank sum test when appropriate. A two-tailed p value of less than 0.05 was considered statistically sig nificant. The correlation between integrated postpran dial plasma cholecystokinin levels and length of postop erative time of follow-up was calculated with the Pear son correlation coefficient.
RESULTS
Fasting and postprandial plasma cholecystokinin levels. Fasting plasma cholecystokinin levels were sig nificantly higher (fi < 0.05) in patients with IPAA (2.6 ± 0.3 pmol/L) compared with the healthy controls (1.7 ± 0.2 pmol/L). Postprandial plasma cholecysto kinin levels increased rapidly and significantly in both groups. In healthy volunteers the mean peak plasma cholecystokinin level was 4.2 ± 0 .5 pmol/L and in pa tients with IPAA 7.8 ± 1.1 pmol/L (p = 0.003). The mean time to peak plasma cholecystokinin levels was similar in both groups* 58 ± 12 minutes in healthy controls and 50 ± 11 minutes in patients with IPAA. Plasma cholecystokinin concentration versus time curves are shown in Fig. 1 . Integrated postprandial plasma cholecystokinin levels were significantly higher Fasting GBVs and postprandial gallbladder emp tying. Fasting GBVs were significantly smaller (p < 0.01) in patients with IPAA (18 ± 2 ml) when compared with healthy controls (27 ± 2 ml). Individual fasting GBVs are shown in Fig. 3 . Mean fasting and postprandial GBVs are depicted in Fig. 4 . Maximum gallbladder emptying was 23 ± 2 ml in controls and 15 ± 3 ml in patients with IPAA (p <0.01). The smallest GBVs were reached at 95 ± 13 minutes in pa- tients with IPAA (3 ± 1 ml) and at 81 ± 7 minutes (not significant) in controls (5 ± 1 ml, not significant). The percentage gallbladder emptying was similar in both groups (controls, 82% ± 3% ; patients with IPAA, 81% ± 4%, not significant). No correlation was ob- 
DISCUSSION
In the present study we have demonstrated that post prandial and bombesin-stimulated plasma cholecysto kinin levels are increased after proctocolectomy with IPAA. To our knowledge this is the first time that the effect of proctocolectomy on plasma cholecystokinin levels and GBVs has been studied in human beings. Probably as a result of fasting hypercholecystokinemia, fasting GBVs are decreased in patients with IPAA. Basal plasma cholecystokinin levels were slightly but significantly elevated after proctocolectomy compared with the healthy controls in our meal study. However, in the bombesin study plasma cholecystokinin levels were similar in both groups. This apparent discrepancy is likely to be due to the small number of subjects in the bombesin experiment compared with the meal study. plasma cholecystokinin levels may have been too low in the bombesin experiment (type II error).
Previously it has been shown that subtotal colectomy results in an increased postprandial plasma cholecysto kinin release in rats and dogs*17*18 Pancreatic weight, digestive enzyme concentration, and secretion capacity increase after large bowel resection in rats.25 These ef fects are supposed to be induced by elevated plasma cholecystokinin levels.
Several mechanisms may account for the increased cholecystokinin levels after proctocolectomy. First, a negative feedback mechanism on the release of chole cystokinin exerted by an unknown inhibiting colonic factor may be eliminated after proctocolectomy. This hypothesis is supported by the finding that perfusion of the colon with oleic acid has been shown to inhibit pan creatic protein secretion in dogs,12 cats,13 and human beings.14,15 Inoue et al. 16 have demonstrated that this inhibition of pancreatic exocrine protein secretion in dogs is due, at least in part, to suppression of cholecys tokinin release. Under normal conditions, however, nu trients like oleic acid do not enter the colon in concen trations used in these perfusion experiments. Therefore it is unclear whether these nutrients play a functional In tegrated cholecystokinin response to bombesin infusion was significantly higher in patients with IPAA {p < 0.05).
declining cholecystokinin levels with time after opera tion, probably as a result of adaptation. It could be speculated that during follow-up after proctocolectomy PYY synthesis in the terminal ileum and circulating PYY levels gradually increase as a result of adaptation. Assuming a suppressive effect of PYY on the release of cholecystokinin, plasma cholecystokinin levels may ini tially increase after proctocolectomy and gradually de cline during follow-up. Previous studies have shown that ileal perfusion of fat emulsions markedly inhibits gastric emptying, small bowel transit, and jejunal motor activity.35"37 This "ileal brake55 correlates well to increased plasma levels of PYY,37 Intravenous infusion of PYY at physiologic lev els slows the mouth to cecum intestinal transit and the rate of gastric emptying.38,39 These data suggest that the ileal brake may be mediated in part by PYY, Small in testine transit is also slowed in patients with IPAA.40 It could be speculated that elevated PYY levels mediate this inhibition of small intestine transit. Removal of the colon does not eliminate the ileal brake because it has been shown that oleic acid infusion into the ileal pouch slows gastric emptying and small intestine transit and 
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increases plasma levels of PYY.41,42 However, it is un clear to what extent stool frequency is influenced by the ileal brake mechanism after proctocolectomy with IPAA. As a result of inflammation of the ileal mucosa, the pro duction of PYY might be decreased in patients with pouchitis. This might contribute to rapid small intestine transit and increased stool frequency in these patients. F u rth er studies are needed to evaluate the role of PYY in the adaptive response during follow-up after procto colectomy with IPAA and the relationship between plasm a levels of PYY and cholecystokinin, in patients both with and without pouchitis. Withdrawal of un known colonic factors with a possible inhibitory effect on th e release of cholecystokinin may also induce hypercholecystokinemia after proctocolectomy.
Previously we have reported that postprandial conju gated serum bile acid levels are decreased in patients with IPAA compared with healthy subjects with an in tact colon.43 An increased fecal excretion of bile acids has been observed in patients with a Kock continent ileostomy44"46 anc[ |n patients with IPAA 47>48 Probably bile acids are reabsorbed less effectively by the ileal pouch mucosa in comparison with the mucosa of the normal term inal ileum. The bile acid pool and the bile acid output into the duodenum decrease if fecal losses are substantial. Because the release of cholecystokinin is in hibited by bile acids in the duodenal lumen,49' 50 elevated plasm a cholecystokinin concentrations after procto colectomy may also be due to a decreased load of bile acids in the proximal part of the small intestine.
In conclusion, basal, postprandial, and bombesinstimulated plasma cholecystokinin levels are elevated after proctocolectomy with ileal pouch-anal anastomo sis in human beings. Probably as a result, fasting GBVs are decreased after proctocolectomy. The mechanisms responsible for hypercholecystokinemia in patients with IP A A are still incompletely understood and need further investigation.
